Trypanosoma cruzi

Classification & Structure

Taxonomy	Kingdom Excavata → Phylum Euglenozoa → Class Kinetoplastea → Order Trypanosomatida → Trypanosoma cruzi (six discrete typing units, DTU I–VI)
Trypomastigote (blood)	15–20 µm; C- or S-shaped; single flagellum; non-replicating form in mammalian blood; large kinetoplast near posterior end; infective to cells
Amastigote	2–5 µm oval; intracellular replicating form; resides in host cell cytoplasm (not phagosome); minimal flagellum; forms pseudocysts of 500+ cells in cardiac/skeletal muscle
Epimastigote	Replicating form in triatomine bug midgut; intermediate kinetoplast; non-infective to mammals; transitions to metacyclic trypomastigotes in hindgut
Metacyclic trypomastigote	Infective form shed in bug faeces; enters host via mucous membranes or breaks in skin; small, 12–15 µm; no surface VSG coat (unlike T. brucei)
Trans-sialidase (TS)	GPI-anchored enzyme transferring sialic acid from host glycoproteins to mucin-like surface glycoproteins (TcMUC); evades complement, enables cell invasion; shed form (tTS) is a key virulence factor and immunogen
GP85 / surface mucins	Heavily sialylated surface coat; complement evasion; receptor for host cell invasion; distinct from T. brucei VSG (no antigenic variation of surface coat)
Kinetoplast DNA	Complex network of maxicircles and minicircles encoding mitochondrial RNAs; minicircle-encoded guide RNAs direct RNA editing; DTU-specific kDNA useful in molecular epidemiology
Reservosomes	Lysosome-related organelles in epimastigotes; store cruzipain (cysteine protease) and lipids; absent in trypomastigotes; cruzipain is a validated drug target

Infection Mechanism & Pathogenesis

• Triatomine transmission & entry routes Triatomine (kissing) bug defecates near bite wound during bloodmeal; metacyclic trypomastigotes in faeces enter via scratch-induced breaks or directly through conjunctiva (Romaña's sign: periorbital oedema). Alternative routes: congenital (5–10% vertical transmission), blood transfusion, organ transplant, oral (contaminated food — outbreaks in Brazil).
• Phagosome escape into cytoplasm Trypomastigotes invade diverse cell types (cardiac myocytes, smooth muscle, macrophages, fibroblasts, neurons) via plasma membrane invagination; initially membrane-bound in a parasitophorous vacuole (PV). Trans-sialidase and TcTox (pore-forming molecule) lyse the PV membrane within 1–2h, releasing amastigotes into the cytoplasm — avoiding lysosomal killing.
• Intracellular replication & pseudocyst formation Amastigotes replicate by binary fission every 12–24h in cytoplasm; accumulate to form pseudocysts of hundreds to thousands in cardiac and skeletal muscle fibres. Pseudocyst rupture releases trypomastigotes into blood → disseminate and invade new cells → inflammatory necrosis of cardiomyocytes and smooth muscle.
• Chronic cardiac pathology — Chagasic cardiomyopathy Years to decades post-infection; characterised by progressive dilated cardiomyopathy, fibrosis, apical ventricular aneurysm (pathognomonic), arrhythmias, right bundle branch block, sudden cardiac death. Pathogenesis: persistent low-level parasitism + autoimmune cross-reactivity (B13 antigen / cardiac myosin) + neuronal destruction of cardiac autonomic ganglia → denervation and fibrosis.
• Chronic gastrointestinal disease — mega-syndromes Destruction of Auerbach's (myenteric) plexus neurons → loss of peristaltic coordination → progressive dilation of oesophagus (megaesophagus: dysphagia, regurgitation) and colon (megacolon: chronic constipation, faecaloma, volvulus). Prevalence varies by geographic DTU (more common DTU VI in southern South America).

Host Immune Response

Disease Spectrum

Stage / Condition	Timing	Key Features	Severity
Acute Chagas disease	Weeks–2 months post-exposure	Fever, malaise, Romaña's sign or chagoma, hepatosplenomegaly; myocarditis in ~1–5%; detectable parasitaemia	Moderate
Indeterminate form (chronic)	Lifelong, ~70% of chronic cases	Seropositive; no organ damage; normal ECG and imaging; may convert to determinate form over decades	Subclinical
Chronic Chagasic cardiomyopathy	10–30 years post-acute	Dilated cardiomyopathy, apical aneurysm, RBBB/LAHB on ECG, VT, sudden death, HF; ~20–30% of infected	Fatal (cardiac)
Megaoesophagus	Chronic, southern South America	Progressive dysphagia, regurgitation, aspiration pneumonia; barium swallow shows dilated oesophagus; achalasia-like	Severe
Megacolon	Chronic	Constipation, faecaloma formation, sigmoid volvulus; surgical risk; DTU VI predominant	Severe
Reactivation (immunosuppressed)	Any time post-infection	HIV/AIDS, transplant recipients; CNS chagoma, myocarditis flare; high parasitaemia; treat as acute	Fatal if untreated

Treatment & Prophylaxis

• Benznidazole — first-line, all phases Nitroimidazole prodrug activated by mitochondrial reductases; generates electrophilic metabolites causing DNA strand breaks and protein adducts in trypanosome. 60 days (adults) / 30–60 days (children); ~80% parasitological cure in acute phase; chronic efficacy ~20–30% by serology conversion. FDA-approved (2017, ages 2–12). GI and skin adverse effects common. Monitor for peripheral neuropathy.
• Nifurtimox — second-line Nitrofuran prodrug; activated by trypanosome Type I nitroreductase to reactive intermediates; oxidative stress-mediated killing. 60–90 days; equivalent acute efficacy to benznidazole but more adverse effects (anorexia, nausea, neurological). Used when benznidazole not tolerated or in reactivation scenarios.
• Cardiac management (chronic) No specific antiparasitic benefit in established cardiomyopathy (BENEFIT trial). Treat HF with standard GDMT (ACEI/ARB, beta-blockers, diuretics); ICD/pacemaker for arrhythmias; anticoagulation for LV thrombus or AF; cardiac transplantation in end-stage (parasitaemia controlled post-transplant with benznidazole).
• Gastrointestinal interventions Megaoesophagus: pneumatic balloon dilation or Heller myotomy; botulinum toxin injection as bridge. Megacolon: laxatives, enemas, fibre; elective sigmoid resection for refractory cases; emergency surgery for volvulus.
• Prevention & screening Indoor residual spraying and improved housing (elimination of triatomine refugia); blood supply screening by serology (mandatory in endemic countries); antenatal screening and congenital treatment within first year (near-100% cure); no vaccine available. Oral transmission outbreaks: cooking/pasteurising açaí, sugar cane juice.

Cross-Atlas Connections

References

• Rassi A Jr, Rassi A, Marin-Neto JA (2010). Chagas disease. Lancet 375(9723):1388–402.
• Bern C (2015). Chagas' disease. N Engl J Med 373(5):456–66.
• Morillo CA et al. (2015). Randomized trial of benznidazole for chronic Chagas' cardiomyopathy (BENEFIT). N Engl J Med 373(14):1295–306.
• Andrews NW et al. (1990). Trypanosoma cruzi secretes a hemolysin that allows its escape from the phagosome. J Exp Med 172(4):1077–85.
• WHO (2023). Chagas disease (American trypanosomiasis). Fact sheet. Geneva: World Health Organization.
• Pérez-Molina JA, Molina I (2018). Chagas disease. Lancet 391(10115):82–94.